乌干达儿童治疗前HIV耐药导致病毒学失败及耐药突变累积
该研究在乌干达纳入317名≤12岁起始一线抗逆转录病毒治疗的儿童,基线及每6个月监测病毒载量并对病毒载量>1000 copies/mL者行基因型耐药检测。结果显示治疗前HIV耐药(PDR)检出率为16.9%(47/278),24个月内32.1%(92/287)发生病毒学失败;PDR是病毒学失败(OR 15.25,P<0.001)和获得性耐药(OR 3.58,P=0.01)的最强预测因素。
要点
- 儿童一线NNRTI方案治疗前HIV耐药检出率达16.9%。
- PDR显著增加病毒学失败和获得性耐药风险。
- 建议≤3岁儿童按WHO指南起始PI为基础方案。
核心结论
- PDR是乌干达儿童一线ART病毒学失败和获得性耐药的最强预测因素。
研究设计与样本
- 前瞻性队列研究纳入317名≤12岁、2010-11年在乌干达起始一线ART的儿童,中位年龄4.9岁,91.5%接受NNRTI为基础方案。
- 基线及每6个月检测病毒载量,病毒载量>1000 copies/mL时行基因型耐药检测,采用2015 IAS-USA突变列表和Stanford算法评分。
- 病毒学失败定义为连续两次病毒载量>1000 copies/mL或ART 6个月后死亡,采用逻辑回归分析失败及获得性耐药相关因素。
主要发现
- 278名儿童中47名(16.9%)检出PDR,其中22名(7.9%)对所使用一线方案耐药而处于部分活性方案。
- 随访24个月,287名儿童中92名(32.1%)发生病毒学失败。
- PDR与病毒学失败风险升高相关(OR 15.25,P<0.001)。
- PDR与获得性耐药风险升高相关(OR 3.58,P=0.01)。
关键数值与推荐
- 病毒学失败判定标准:连续两次病毒载量>1000 copies/mL或ART 6个月后死亡。
- 耐药突变评分采用2015 IAS-USA突变列表和Stanford算法。
- WHO指南推荐≤3岁儿童起始PI为基础方案。
临床怎么用
- 对起始一线NNRTI方案的儿童应关注PDR并考虑常规病毒载量监测以早期发现病毒学失败。
- ≤3岁儿童应按WHO指南起始PI为基础方案以降低PDR影响。
- 存在PDR时需选择最大化一线疗效的方案以确保长期治疗成功。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretreatment HIV drug resistance (PDR) can impair virological response to ART, jeopardizing effective treatment for children. METHODS: Children aged ≤12 years initiated first-line ART in Uganda during 2010-11. Baseline and 6 monthly viral load (VL) and genotypic resistance testing if VL >1000 copies/mL was done. The 2015 IAS-USA mutation list and Stanford algorithm were used to score drug resistance mutations (DRMs) and susceptibility. Virological failure (VF) was defined as two consecutive VLs >1000 copies/mL or death after 6 months of ART. Factors associated with failure and acquired drug resistance (ADR) were assessed in a logistic regression analysis. RESULTS: Among 317 children enrolled, median age was 4.9 years and 91.5% received NNRTI-based regimens. PDR was detected in 47/278 (16.9%) children, of whom 22 (7.9%) had resistance against their first-line regimen and were therefore on a partially active regimen. After 24 months of follow-up, 92/287 (32.1%) had experienced VF. Children with PDR had a higher risk of VF (OR 15.25, P < 0.001) and ADR (OR 3.58, P = 0.01). CONCLUSIONS: Almost one-third of children experienced VF within 24 months of NNRTI-based first-line treatment. PDR was the strongest predictor of VF and ADR, and therefore presents a major threat in children. There is a need for ART regimens that maximize effectiveness of first-line therapy for long-term treatment success in the presence of PDR or incorporation of routine VL testing to detect VF and change treatment in time, in order to prevent clinical deterioration and accumulation of additional drug resistance. Children ≤3 years should be initiated on a PI-based regimen as per WHO guidelines.
引用
- Kityo C, Boerma RS, Sigaloff KCE, et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother. 2017. PMID: 28673027. doi:10.1093/jac/dkx188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。